title: Results of T-depleted BMT in chronic myelogenous leukaemia after a conditioning regimen that included thiotepa.
authors.affiliation: Institute of Haematology, University of Perugia, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Aversa
authors.forename: P G
authors.initials: PG
authors.lastname: Pelicci
authors.forename: A
authors.initials: A
authors.lastname: Terenzi
authors.forename: A
authors.initials: A
authors.lastname: Carotti
authors.forename: R
authors.initials: R
authors.lastname: Felicini
authors.forename: A
authors.initials: A
authors.lastname: Mencarelli
authors.forename: E
authors.initials: E
authors.lastname: Donti
authors.forename: P
authors.initials: P
authors.lastname: Latini
authors.forename: C
authors.initials: C
authors.lastname: Aristei
authors.forename: M F
authors.initials: MF
authors.lastname: Martelli
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000379:methods*; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000032:analysis; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D008212:Lymphocyte Depletion; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000032:analysis; D012334:RNA, Neoplasm / Q000032:analysis; D013601:T-Lymphocytes; D013852:Thiotepa / Q000627:therapeutic use*
chemical_list: D012333:RNA, Messenger; D012334:RNA, Neoplasm; D013852:Thiotepa; D016044:Fusion Proteins, bcr-abl